Baidu
map

消化

订阅

MedSci主页 / 所有栏目 / 消化

抗体药物偶联物OBI-999治疗胰腺癌获得FDA孤儿药物认定

2019-12-27 Allan MedSci原创

抗体药物偶联物OBI-999胰腺癌
关注

台湾OBI制药公司近日宣布，美国FDA已授予OBI-999孤儿药认定，用于治疗胰腺癌。OBI-999是靶向Globo H（糖脂抗原）的抗体药物偶联物。

台湾OBI制药公司近日宣布，美国FDA已授予OBI-999孤儿药认定，用于治疗胰腺癌。OBI-999是靶向Globo H（糖脂抗原）的抗体药物偶联物。OBI-999的I/II期临床试验已在德克萨斯大学MD安德森癌症中心招募，用于治疗局部晚期或转移性实体瘤（包括胰腺癌、胃癌、结直肠癌和食道癌）患者。该试验的目的是验证OBI-999在这些患​​者人群中的安全性和初步疗效。

OBI制药公司的首席医学官Tillman Pearce指出：“鉴于我们在胰腺癌异种移植物模型中使用OBI-999观察到的显著有效性，我们对OBI-999可能为胰腺癌患者提供的潜在价值感到非常兴奋。许多胰腺癌患者高度表达Globo H（OBI-999的糖脂靶标）”。


原始出处：

http://www.firstwordpharma.com/node/1690056#axzz69CnI0iLA

本文系梅斯医学（MedSci）原创编译整理，转载需授权!

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1957624, encodeId=e317195e624f6, content=<a href='/topic/show?id=a09c551998a' target=_blank style='color:#2F92EE;'>#抗体药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55199, encryptionId=a09c551998a, topicName=抗体药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=793a2500200, createdName=12498e5fm12(暂无昵称), createdTime=Wed Aug 12 05:14:00 CST 2020, time=2020-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2016172, encodeId=452320161e27d, content=<a href='/topic/show?id=d0565520072' target=_blank style='color:#2F92EE;'>#抗体药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55200, encryptionId=d0565520072, topicName=抗体药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e6a1280, createdName=zhanglin3079, createdTime=Tue Oct 27 12:14:00 CST 2020, time=2020-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1740117, encodeId=a3361e4011723, content=<a href='/topic/show?id=f5a445431df' target=_blank style='color:#2F92EE;'>#孤儿药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45431, encryptionId=f5a445431df, topicName=孤儿药物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a4f034650217, createdName=ms6980045490879608, createdTime=Thu Jun 25 09:14:00 CST 2020, time=2020-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1968626, encodeId=379c196862659, content=<a href='/topic/show?id=06c61320419' target=_blank style='color:#2F92EE;'>#OBI-999#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13204, encryptionId=06c61320419, topicName=OBI-999)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=010d202, createdName=amy0550, createdTime=Fri Jul 31 13:14:00 CST 2020, time=2020-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1413823, encodeId=db20141382377, content=<a href='/topic/show?id=ce4a55202f0' target=_blank style='color:#2F92EE;'>#抗体药物偶联物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55202, encryptionId=ce4a55202f0, topicName=抗体药物偶联物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f5ea3025344, createdName=chendoc243, createdTime=Sun Dec 29 07:14:00 CST 2019, time=2019-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1615969, encodeId=310d161596945, content=<a href='/topic/show?id=519345433ea' target=_blank style='color:#2F92EE;'>#孤儿药物认定#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45433, encryptionId=519345433ea, topicName=孤儿药物认定)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8cfd19711155, createdName=若水129, createdTime=Sun Dec 29 07:14:00 CST 2019, time=2019-12-29, status=1, ipAttribution=)]
    2020-08-12 12498e5fm12(暂无昵称)

    #抗体药#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1957624, encodeId=e317195e624f6, content=<a href='/topic/show?id=a09c551998a' target=_blank style='color:#2F92EE;'>#抗体药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55199, encryptionId=a09c551998a, topicName=抗体药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=793a2500200, createdName=12498e5fm12(暂无昵称), createdTime=Wed Aug 12 05:14:00 CST 2020, time=2020-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2016172, encodeId=452320161e27d, content=<a href='/topic/show?id=d0565520072' target=_blank style='color:#2F92EE;'>#抗体药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55200, encryptionId=d0565520072, topicName=抗体药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e6a1280, createdName=zhanglin3079, createdTime=Tue Oct 27 12:14:00 CST 2020, time=2020-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1740117, encodeId=a3361e4011723, content=<a href='/topic/show?id=f5a445431df' target=_blank style='color:#2F92EE;'>#孤儿药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45431, encryptionId=f5a445431df, topicName=孤儿药物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a4f034650217, createdName=ms6980045490879608, createdTime=Thu Jun 25 09:14:00 CST 2020, time=2020-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1968626, encodeId=379c196862659, content=<a href='/topic/show?id=06c61320419' target=_blank style='color:#2F92EE;'>#OBI-999#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13204, encryptionId=06c61320419, topicName=OBI-999)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=010d202, createdName=amy0550, createdTime=Fri Jul 31 13:14:00 CST 2020, time=2020-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1413823, encodeId=db20141382377, content=<a href='/topic/show?id=ce4a55202f0' target=_blank style='color:#2F92EE;'>#抗体药物偶联物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55202, encryptionId=ce4a55202f0, topicName=抗体药物偶联物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f5ea3025344, createdName=chendoc243, createdTime=Sun Dec 29 07:14:00 CST 2019, time=2019-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1615969, encodeId=310d161596945, content=<a href='/topic/show?id=519345433ea' target=_blank style='color:#2F92EE;'>#孤儿药物认定#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45433, encryptionId=519345433ea, topicName=孤儿药物认定)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8cfd19711155, createdName=若水129, createdTime=Sun Dec 29 07:14:00 CST 2019, time=2019-12-29, status=1, ipAttribution=)]
    2020-10-27 zhanglin3079

    #抗体药物#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1957624, encodeId=e317195e624f6, content=<a href='/topic/show?id=a09c551998a' target=_blank style='color:#2F92EE;'>#抗体药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55199, encryptionId=a09c551998a, topicName=抗体药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=793a2500200, createdName=12498e5fm12(暂无昵称), createdTime=Wed Aug 12 05:14:00 CST 2020, time=2020-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2016172, encodeId=452320161e27d, content=<a href='/topic/show?id=d0565520072' target=_blank style='color:#2F92EE;'>#抗体药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55200, encryptionId=d0565520072, topicName=抗体药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e6a1280, createdName=zhanglin3079, createdTime=Tue Oct 27 12:14:00 CST 2020, time=2020-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1740117, encodeId=a3361e4011723, content=<a href='/topic/show?id=f5a445431df' target=_blank style='color:#2F92EE;'>#孤儿药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45431, encryptionId=f5a445431df, topicName=孤儿药物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a4f034650217, createdName=ms6980045490879608, createdTime=Thu Jun 25 09:14:00 CST 2020, time=2020-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1968626, encodeId=379c196862659, content=<a href='/topic/show?id=06c61320419' target=_blank style='color:#2F92EE;'>#OBI-999#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13204, encryptionId=06c61320419, topicName=OBI-999)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=010d202, createdName=amy0550, createdTime=Fri Jul 31 13:14:00 CST 2020, time=2020-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1413823, encodeId=db20141382377, content=<a href='/topic/show?id=ce4a55202f0' target=_blank style='color:#2F92EE;'>#抗体药物偶联物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55202, encryptionId=ce4a55202f0, topicName=抗体药物偶联物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f5ea3025344, createdName=chendoc243, createdTime=Sun Dec 29 07:14:00 CST 2019, time=2019-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1615969, encodeId=310d161596945, content=<a href='/topic/show?id=519345433ea' target=_blank style='color:#2F92EE;'>#孤儿药物认定#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45433, encryptionId=519345433ea, topicName=孤儿药物认定)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8cfd19711155, createdName=若水129, createdTime=Sun Dec 29 07:14:00 CST 2019, time=2019-12-29, status=1, ipAttribution=)]
    2020-06-25 ms6980045490879608

    #孤儿药物#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1957624, encodeId=e317195e624f6, content=<a href='/topic/show?id=a09c551998a' target=_blank style='color:#2F92EE;'>#抗体药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55199, encryptionId=a09c551998a, topicName=抗体药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=793a2500200, createdName=12498e5fm12(暂无昵称), createdTime=Wed Aug 12 05:14:00 CST 2020, time=2020-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2016172, encodeId=452320161e27d, content=<a href='/topic/show?id=d0565520072' target=_blank style='color:#2F92EE;'>#抗体药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55200, encryptionId=d0565520072, topicName=抗体药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e6a1280, createdName=zhanglin3079, createdTime=Tue Oct 27 12:14:00 CST 2020, time=2020-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1740117, encodeId=a3361e4011723, content=<a href='/topic/show?id=f5a445431df' target=_blank style='color:#2F92EE;'>#孤儿药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45431, encryptionId=f5a445431df, topicName=孤儿药物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a4f034650217, createdName=ms6980045490879608, createdTime=Thu Jun 25 09:14:00 CST 2020, time=2020-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1968626, encodeId=379c196862659, content=<a href='/topic/show?id=06c61320419' target=_blank style='color:#2F92EE;'>#OBI-999#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13204, encryptionId=06c61320419, topicName=OBI-999)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=010d202, createdName=amy0550, createdTime=Fri Jul 31 13:14:00 CST 2020, time=2020-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1413823, encodeId=db20141382377, content=<a href='/topic/show?id=ce4a55202f0' target=_blank style='color:#2F92EE;'>#抗体药物偶联物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55202, encryptionId=ce4a55202f0, topicName=抗体药物偶联物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f5ea3025344, createdName=chendoc243, createdTime=Sun Dec 29 07:14:00 CST 2019, time=2019-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1615969, encodeId=310d161596945, content=<a href='/topic/show?id=519345433ea' target=_blank style='color:#2F92EE;'>#孤儿药物认定#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45433, encryptionId=519345433ea, topicName=孤儿药物认定)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8cfd19711155, createdName=若水129, createdTime=Sun Dec 29 07:14:00 CST 2019, time=2019-12-29, status=1, ipAttribution=)]
    2020-07-31 amy0550

    #OBI-999#

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1957624, encodeId=e317195e624f6, content=<a href='/topic/show?id=a09c551998a' target=_blank style='color:#2F92EE;'>#抗体药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55199, encryptionId=a09c551998a, topicName=抗体药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=793a2500200, createdName=12498e5fm12(暂无昵称), createdTime=Wed Aug 12 05:14:00 CST 2020, time=2020-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2016172, encodeId=452320161e27d, content=<a href='/topic/show?id=d0565520072' target=_blank style='color:#2F92EE;'>#抗体药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55200, encryptionId=d0565520072, topicName=抗体药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e6a1280, createdName=zhanglin3079, createdTime=Tue Oct 27 12:14:00 CST 2020, time=2020-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1740117, encodeId=a3361e4011723, content=<a href='/topic/show?id=f5a445431df' target=_blank style='color:#2F92EE;'>#孤儿药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45431, encryptionId=f5a445431df, topicName=孤儿药物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a4f034650217, createdName=ms6980045490879608, createdTime=Thu Jun 25 09:14:00 CST 2020, time=2020-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1968626, encodeId=379c196862659, content=<a href='/topic/show?id=06c61320419' target=_blank style='color:#2F92EE;'>#OBI-999#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13204, encryptionId=06c61320419, topicName=OBI-999)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=010d202, createdName=amy0550, createdTime=Fri Jul 31 13:14:00 CST 2020, time=2020-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1413823, encodeId=db20141382377, content=<a href='/topic/show?id=ce4a55202f0' target=_blank style='color:#2F92EE;'>#抗体药物偶联物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55202, encryptionId=ce4a55202f0, topicName=抗体药物偶联物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f5ea3025344, createdName=chendoc243, createdTime=Sun Dec 29 07:14:00 CST 2019, time=2019-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1615969, encodeId=310d161596945, content=<a href='/topic/show?id=519345433ea' target=_blank style='color:#2F92EE;'>#孤儿药物认定#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45433, encryptionId=519345433ea, topicName=孤儿药物认定)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8cfd19711155, createdName=若水129, createdTime=Sun Dec 29 07:14:00 CST 2019, time=2019-12-29, status=1, ipAttribution=)]
    2019-12-29 chendoc243

    #抗体药物偶联物#

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1957624, encodeId=e317195e624f6, content=<a href='/topic/show?id=a09c551998a' target=_blank style='color:#2F92EE;'>#抗体药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55199, encryptionId=a09c551998a, topicName=抗体药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=793a2500200, createdName=12498e5fm12(暂无昵称), createdTime=Wed Aug 12 05:14:00 CST 2020, time=2020-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2016172, encodeId=452320161e27d, content=<a href='/topic/show?id=d0565520072' target=_blank style='color:#2F92EE;'>#抗体药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55200, encryptionId=d0565520072, topicName=抗体药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e6a1280, createdName=zhanglin3079, createdTime=Tue Oct 27 12:14:00 CST 2020, time=2020-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1740117, encodeId=a3361e4011723, content=<a href='/topic/show?id=f5a445431df' target=_blank style='color:#2F92EE;'>#孤儿药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45431, encryptionId=f5a445431df, topicName=孤儿药物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a4f034650217, createdName=ms6980045490879608, createdTime=Thu Jun 25 09:14:00 CST 2020, time=2020-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1968626, encodeId=379c196862659, content=<a href='/topic/show?id=06c61320419' target=_blank style='color:#2F92EE;'>#OBI-999#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13204, encryptionId=06c61320419, topicName=OBI-999)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=010d202, createdName=amy0550, createdTime=Fri Jul 31 13:14:00 CST 2020, time=2020-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1413823, encodeId=db20141382377, content=<a href='/topic/show?id=ce4a55202f0' target=_blank style='color:#2F92EE;'>#抗体药物偶联物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55202, encryptionId=ce4a55202f0, topicName=抗体药物偶联物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f5ea3025344, createdName=chendoc243, createdTime=Sun Dec 29 07:14:00 CST 2019, time=2019-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1615969, encodeId=310d161596945, content=<a href='/topic/show?id=519345433ea' target=_blank style='color:#2F92EE;'>#孤儿药物认定#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45433, encryptionId=519345433ea, topicName=孤儿药物认定)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8cfd19711155, createdName=若水129, createdTime=Sun Dec 29 07:14:00 CST 2019, time=2019-12-29, status=1, ipAttribution=)]
    2019-12-29 若水129

    #孤儿药物认定#

    0

相关资讯

抗体药物偶联物治疗肺癌：U3-1402和DS-1062的临床结果更新将在2019年世界肺癌大会上发表

Daiichi Sankyo（第一三共株式会社）近日宣布，以评估抗体药物偶联物（ADC）U3-1402和DS-1062治疗晚期或转移性非小细胞肺癌（NSCLC）的最新数据将于2019年9月7日至10日在世界肺癌大会上发表。

欧盟批准武田抗癌药Adcetris用于霍奇金淋巴瘤患者干细胞移植后的巩固治疗

日本制药巨头武田（Takeda）抗癌管线近日在欧盟监管方面传来喜讯，欧盟委员会（EC）已批准扩大抗体药物偶联物（ADC）Adcetris（brentuximab vedotin）当前的有条件批准，用于接受自体干细胞移植（ASCT）后具有升高的复发或进展风险的CD30阳性霍奇金淋巴瘤（HL）成人患者的巩固治疗。当前，自体干细胞移植（ASCT）是霍奇金淋巴瘤患者一线化疗失败后的标准护理，但高达50

阿斯利康靶向HER2的抗体药物偶联物在II期临床试验中显示出治疗前景

阿斯利康宣布其与Daiichi Sankyo联合开发的靶向的HER2抗体药物偶联物（ADC）治疗乳腺癌，已在II期试验中达到其主要终点。

Baidu
map
Baidu
map
Baidu
map